JP2008518943A5 - - Google Patents

Info

Publication number

JP2008518943A5

JP2008518943A5 JP2007539241A JP2007539241A JP2008518943A5 JP 2008518943 A5 JP2008518943 A5 JP 2008518943A5 JP 2007539241 A JP2007539241 A JP 2007539241A JP 2007539241 A JP2007539241 A JP 2007539241A JP 2008518943 A5 JP2008518943 A5 JP 2008518943A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

hours

composition according

patient

administration

Prior art date

2005-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 36
• 241000711549 Hepacivirus C Species 0.000 claims 7
• 239000002552 dosage form Substances 0.000 claims 7
• 239000003112 inhibitor Substances 0.000 claims 6
• 102000014150 Interferons Human genes 0.000 claims 3
• 108010050904 Interferons Proteins 0.000 claims 3
• 229940079322 interferon Drugs 0.000 claims 3
• 230000036470 plasma concentration Effects 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• 231100000240 steatosis hepatitis Toxicity 0.000 claims 3
• 108091005804 Peptidases Proteins 0.000 claims 2
• 239000004365 Protease Substances 0.000 claims 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 229960000329 ribavirin Drugs 0.000 claims 2
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
• 230000007863 steatosis Effects 0.000 claims 2
• 230000003612 virological effect Effects 0.000 claims 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
• 108010082126 Alanine transaminase Proteins 0.000 claims 1
• 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
• 208000004930 Fatty Liver Diseases 0.000 claims 1
• 206010019708 Hepatic steatosis Diseases 0.000 claims 1
• 241000282412 Homo Species 0.000 claims 1
• 102000006992 Interferon-alpha Human genes 0.000 claims 1
• 108010047761 Interferon-alpha Proteins 0.000 claims 1
• 102000003996 Interferon-beta Human genes 0.000 claims 1
• 108090000467 Interferon-beta Proteins 0.000 claims 1
• 102000008070 Interferon-gamma Human genes 0.000 claims 1
• 108010074328 Interferon-gamma Proteins 0.000 claims 1
• 206010067125 Liver injury Diseases 0.000 claims 1
• 102000005741 Metalloproteases Human genes 0.000 claims 1
• 108010006035 Metalloproteases Proteins 0.000 claims 1
• 108060004795 Methyltransferase Proteins 0.000 claims 1
• 201000007981 Reye syndrome Diseases 0.000 claims 1
• 102000007501 Thymosin Human genes 0.000 claims 1
• 108010046075 Thymosin Proteins 0.000 claims 1
• 208000036142 Viral infection Diseases 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 230000001476 alcoholic effect Effects 0.000 claims 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
• 229960003805 amantadine Drugs 0.000 claims 1
• 239000003443 antiviral agent Substances 0.000 claims 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
• 208000010706 fatty liver disease Diseases 0.000 claims 1
• 229940044627 gamma-interferon Drugs 0.000 claims 1
• 231100000234 hepatic damage Toxicity 0.000 claims 1
• 208000006454 hepatitis Diseases 0.000 claims 1
• 231100000283 hepatitis Toxicity 0.000 claims 1
• 230000002519 immonomodulatory effect Effects 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 230000008818 liver damage Effects 0.000 claims 1
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
• 230000002459 sustained effect Effects 0.000 claims 1
• IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
• 229960005311 telbivudine Drugs 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical group SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
• 230000009385 viral infection Effects 0.000 claims 1